{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:35:09Z","timestamp":1776353709406,"version":"3.51.2"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.clcc.2023.02.007","type":"journal-article","created":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T02:00:35Z","timestamp":1677895235000},"page":"238-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Incidence of Disease Recurrence in Patients With Colon and Upper Rectum Adenocarcinoma Stage II and III Receiving Adjuvant Capecitabine Monotherapy: Do Number of Chemotherapy Cycles and Relative Dose Intensity of the Drug Play a Role?"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5537-3611","authenticated-orcid":false,"given":"Joseph","family":"Sgouros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Gkoura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Spathas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fotios","family":"Tzoudas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Karampinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Miaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios","family":"Visvikis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Dessypris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Mauri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerasimos","family":"Aravantinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilias","family":"Theodoropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Stamoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Epaminondas","family":"Samantas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clcc.2023.02.007_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.clcc.2023.02.007_bib0002","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.3390\/cancers12082289","article-title":"Adjuvant chemotherapy in elderly colorectal cancer patients","volume":"12","author":"Glimelius","year":"2020","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.clcc.2023.02.007_bib0003","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localized colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Argil\u00e9s","year":"2020","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.clcc.2023.02.007_bib0004","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2023.02.007_bib0005","article-title":"The association of comorbidities with administration of adjuvant chemotherapy in stage III colon cancer patients: a systematic review and meta-analysis","volume":"13","author":"Boakye","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"26","key":"10.1016\/j.clcc.2023.02.007_bib0006","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1056\/NEJMoa043116","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer","volume":"352","author":"Twelves","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clcc.2023.02.007_bib0007","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/annonc\/mdr329","article-title":"Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer","volume":"23","author":"Chang","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2023.02.007_bib0008","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"issue":"2","key":"10.1016\/j.clcc.2023.02.007_bib0009","first-page":"144","article-title":"Relative dose intensity of systemic chemotherapy in an outpatient cancer center","volume":"39","author":"Uptigrove","year":"2010","journal-title":"Acta Medica Academica"},{"issue":"11","key":"10.1016\/j.clcc.2023.02.007_bib0010","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1200\/JCO.1991.9.11.2042","article-title":"The calculation of actual or received dose intensity: a comparison of published methods","volume":"9","author":"Longo","year":"1991","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clcc.2023.02.007_bib0011","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2023.02.007_bib0012","series-title":"SAS\u00ae 9.4 Statements: Reference. Cary","year":"2013"},{"issue":"13","key":"10.1016\/j.clcc.2023.02.007_bib0013","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/jnci\/djm024","article-title":"Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials","volume":"99","author":"Punt","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.clcc.2023.02.007_bib0014","first-page":"13","article-title":"Reintroduction of irinotecan and oxaliplatin as a combination (IROX) in heavily pretreated colorectal cancer patients. A single center experience","volume":"4","author":"Sgouros","year":"2013","journal-title":"Forum Clin Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2023.02.007_bib0015","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ijc.30423","article-title":"Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy","volume":"140","author":"van Erning","year":"2017","journal-title":"Int J Cancer"},{"issue":"suppl 15","key":"10.1016\/j.clcc.2023.02.007_bib0016","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1200\/jco.2010.28.15_suppl.3624","article-title":"Association of survival outcomes with dose intensity of adjuvant therapy (AT) with capecitabine for colorectal cancer (CRC)","volume":"28","author":"Ho","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2023.02.007_bib0017","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12885-015-1038-y","article-title":"Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans","volume":"15","author":"Aspinall","year":"2015","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.clcc.2023.02.007_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.4154","article-title":"Association between adjuvant chemotherapy duration and survival among patients with stage II and III colon cancer: a systematic review and meta-analysis","volume":"2","author":"Boyne","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.clcc.2023.02.007_bib0019","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.3390\/curroncol28050342","article-title":"The influence of adjuvant chemotherapy dose intensity on five-year outcomes in resected colon cancer: a single centre retrospective analysis","volume":"28","author":"Lakkunarajah","year":"2021","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.clcc.2023.02.007_bib0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s12029-015-9746-8","article-title":"Impact of dose reductions, delays between chemotherapy cycles, and\/or shorter courses of adjuvant chemotherapy in stage II and III colorectal cancer patients: a single-center retrospective study","volume":"46","author":"Sgouros","year":"2015","journal-title":"J Gastrointest Cancer"},{"issue":"7","key":"10.1016\/j.clcc.2023.02.007_bib0021","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.annonc.2020.03.310","article-title":"Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study","volume":"31","author":"Pag\u00e8s","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.clcc.2023.02.007_bib0022","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.annonc.2022.03.002","article-title":"Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)","volume":"33","author":"Basile","year":"2022","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.clcc.2023.02.007_bib0023","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002823000245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002823000245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:07:53Z","timestamp":1761520073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002823000245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1533002823000245"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2023.02.007","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of Disease Recurrence in Patients With Colon and Upper Rectum Adenocarcinoma Stage II and III Receiving Adjuvant Capecitabine Monotherapy: Do Number of Chemotherapy Cycles and Relative Dose Intensity of the Drug Play a Role?","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2023.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}